Real-world experience of metformin 1000 mg/day in patients with type 2 diabetes mellitus and comorbidities from Myanmar
| Autor: | Soe Yarzar, Myo Lin Aung, Thet Kyaw Soe, Aung Ko Ko Win, Thuzar Lwan Thar, Santosh Revankar, Tripti Sharmaa |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | International Journal of Research in Medical Sciences. 10:867 |
| ISSN: | 2320-6012 2320-6071 |
| DOI: | 10.18203/2320-6012.ijrms20220978 |
| Popis: | Background: The study was conducted to assess the efficacy and safety of 1000 (mg/day) metformin in patients with type 2 diabetes (T2DM) with comorbidities and special reference to elderly people in Myanmar.Methods: This was a retrospective, post surveillance study conducted in patients diagnosed with T2DM receiving treatment of metformin (1000 mg/day). Baseline characteristics, comorbidities, random blood sugar level (RBS) and RBS changes pre- and post-therapy were retrieved from patient’s medical records. A paired sample t-test was used for comparing the pre- and post-treatment RBS levels.Results: A total of 303 patients with T2DM were included. A total of 88, 115 and 100 patients belonged to age groups ≤50, >50-≤60 and >61 years, respectively. Duration of T2DM was significantly higher in elderly patients (>61 years) compared to ≤50 and >50-≤60 age group. Hypertension was the most common comorbid condition observed in all age groups followed by cardiovascular disease. However, both hypertension and cardiovascular disease were significantly higher among elderly patients (>61 years) compared to ≤50 and >50-≤60 age group (p50-≤60 years, 86.2 mg/dL and >61 years, 97.2 mg/dL). Metformin was well tolerated with minimal gastrointestinal adverse events (n=27).Conclusions: In this post marketing surveillance study, metformin (1000 mg/day) was found to be effective in reducing RBS in T2DM patients with comorbidities especially older adults and well tolerated with no risk of hypoglycemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|